首页> 外文期刊>Pancreas >Clinical characteristics of adenosquamous carcinoma of the pancreas: A matched case-control study
【24h】

Clinical characteristics of adenosquamous carcinoma of the pancreas: A matched case-control study

机译:胰腺腺鳞癌的临床特征:病例对照研究

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: Adenosquamous carcinoma of the pancreas (ASC) is a variant of pancreatic ductal adenocarcinoma (PDAC), but the prognosis remains unclear. The purpose of this study was to clarify the prognosis of ASC using a matched case-control design. METHODS: We evaluated clinical characteristics of ASC treated between 2001 and 2011 in our institution. As controls, PDAC cases matched with ASC cases for sex, age, pretreatment Eastern Cooperative Oncology Group performance status, location, initial therapy and American Joint Committee on Cancer TNM staging for pancreatic cancer were also evaluated. RESULTS: Of the 914 cases of pancreatic neoplasm, 28 cases (3.06%) of ASC were identified, and 56 cases of PDAC were matched as controls. Median overall survival (OS) was significantly worse for ASC (8.38 months) than for PDAC (15.75 months; hazard ratio [HR], 1.94; 95% confidence interval, 1.07-3.51; P = 0.026). Of the 22 unresected cases, median OS was again significantly worse for ASC (4.67 months) than for PDAC (12.36 months; HR, 2.39; 95% confidence interval, 1.27-4.51; P = 0.007). CONCLUSION: These results demonstrate that ASC is more aggressive than PDAC.
机译:目的:胰腺腺鳞癌(ASC)是胰腺导管腺癌(PDAC)的一种变体,但预后尚不清楚。这项研究的目的是使用匹配的病例对照设计来阐明ASC的预后。方法:我们评估了我院2001年至2011年治疗的ASC的临床特征。作为对照,还评估了PDAC病例与ASC病例的性别,年龄,治疗前的东方合作肿瘤小组的表现状态,位置,初始治疗以及美国胰腺癌TNM分期联合委员会对胰腺癌的匹配情况。结果:在914例胰腺肿瘤中,鉴定出28例(3.06%)ASC,56例PDAC作为对照。 ASC(8.38个月)的中位总体生存(OS)显着差于PDAC(15.75个月;危险比[HR]为1.94; 95%置信区间为1.07-3.51; P = 0.026)。在22例未切除的病例中,ASC(4.67个月)的中位OS再次显着低于PDAC(12.36个月; HR,2.39; 95%置信区间,1.27-4.51; P = 0.007)。结论:这些结果表明,ASC比PDAC更具侵略性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号